India's CRI-Kasauli Unveils Innovative Single-Dose Vaccine for Tetanus and Diphtheria

The Central Research Institute in Kasauli has made a groundbreaking advancement by developing a single-dose vaccine that protects against both tetanus and diphtheria. This innovative vaccine, which has successfully completed clinical trials, aims to simplify immunization schedules and enhance vaccine compliance. Health experts believe it will significantly reduce the incidence of these diseases, particularly among children. Established in 1905, CRI-Kasauli has a rich history in vaccine research and continues to play a crucial role in India's public health initiatives. The formal launch of this vaccine is expected soon, marking a significant milestone in disease prevention efforts.

By Narendra Chaudhary Dec 23, 2025, 16:25 IST

Significant Advancement in Public Health

Shimla: In a remarkable advancement for India's public health initiatives, the Central Research Institute (CRI) located in Kasauli, Himachal Pradesh, has successfully developed a single-dose vaccine that provides protection against both tetanus and diphtheria.

The vaccine has completed its clinical trials with positive results, demonstrating its efficacy in producing antibodies for both diseases. A formal launch by Union Health Minister JP Nadda is anticipated soon, with plans for distribution in government hospitals shortly thereafter.

Transition from Two Injections to One

Previously, vaccinations for tetanus and diphtheria required separate doses, which often led to discomfort and logistical issues, particularly for young children. Research at CRI-Kasauli aimed to merge these two vaccines into a single injection, beginning in 2019.

Despite challenges posed by the Covid-19 pandemic, the research team persevered and has now achieved a significant breakthrough with a combined formulation that is both safe and effective.

Promising Clinical Trial Outcomes

All necessary clinical trial phases have been successfully completed, showing a robust antibody response to both tetanus and diphtheria.

According to a scientist from CRI-Kasauli, the trials confirmed the vaccine's effectiveness and compliance with safety standards. The vaccine is set to be introduced soon through the public healthcare system.

Impact on Public Health

Health professionals anticipate that this new vaccine will significantly aid in preventing tetanus infections from cuts and wounds, as well as diphtheria, which primarily affects children but can impact individuals of all ages.

CRI-Kasauli's Legacy in Vaccine Development

Founded on May 3, 1905, the Central Research Institute in Kasauli is one of India's oldest and most esteemed vaccine research institutions. For over a century, it has been pivotal in vaccine and serum production, making substantial contributions to public health both domestically and internationally.

The CRI also played a vital role in treating injured soldiers during World War II and was the first central government facility in India to produce the DPT vaccine.

With the introduction of the combined tetanus-diphtheria vaccine, CRI-Kasauli continues to solidify its status as a cornerstone of India's immunization and disease prevention strategies.